Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.

Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardanani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, Litzow MR.

Eur J Haematol. 2012 Mar;88(3):237-43. doi: 10.1111/j.1600-0609.2011.01727.x. Epub 2011 Nov 17.

PMID:
22023492
2.

Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience.

Pulsoni A, Pagano L, Lo Coco F, Avvisati G, Mele L, Di Bona E, Invernizzi R, Leoni F, Marmont F, Mele A, Melillo L, Nosari AM, Pogliani EM, Vignetti M, Visani G, Zagonel V, Leone G, Mandelli F.

Blood. 2002 Sep 15;100(6):1972-6.

3.

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P.

Blood. 1998 Oct 15;92(8):2712-8.

4.

Long-term survey of outcome in acute promyelocytic leukemia.

Hu J, Shen Z, Sun H, Wu W, Li X, Sun G, Wang Z.

Chin Med J (Engl). 2000 Feb;113(2):107-10.

PMID:
11775530
5.

Comparison of anthracycline-based combination chemotherapy with or without all-trans retinoic acid in acute promyelocytic leukemia.

Raza S, Ullah K, Ahmed P, Khan B.

J Coll Physicians Surg Pak. 2008 Sep;18(9):546-50. doi: 09.2008/JCPSP.546550.

PMID:
18803891
6.

Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.

Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, et al.

Blood. 1995 Sep 1;86(5):1717-28.

7.

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P.

J Clin Oncol. 2005 Jan 1;23(1):120-6. Epub 2004 Nov 8.

PMID:
15534358
8.

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA.

Haematologica. 2010 Mar;95(3):424-31. doi: 10.3324/haematol.2009.013243. Epub 2009 Nov 10.

9.

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.

Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Román J, Barragán E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatías Malignas.

Blood. 2004 Feb 15;103(4):1237-43. Epub 2003 Oct 23.

10.

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L.

J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.

PMID:
19414681
11.

All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.

Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, et al.

Blood. 1995 Mar 1;85(5):1202-6.

12.

Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.

Montesinos P, González JD, González J, Rayón C, de Lisa E, Amigo ML, Ossenkoppele GJ, Peñarrubia MJ, Pérez-Encinas M, Bergua J, Debén G, Sayas MJ, de la Serna J, Ribera JM, Bueno J, Milone G, Rivas C, Brunet S, Löwenberg B, Sanz M.

J Clin Oncol. 2010 Aug 20;28(24):3872-9. doi: 10.1200/JCO.2010.29.2268. Epub 2010 Jul 12.

PMID:
20625122
13.

All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).

Chim CS, Kwong YL, Liang R, Chu YC, Chan CH, Chan LC, Wong KF, Chan TK.

Hematol Oncol. 1996 Sep;14(3):147-54.

PMID:
9119359
14.

Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.

Gupta V, Yib QL, Brandwein J, Chun K, Lipton JH, Messner H, Schuh AC, Wells RA, Minden MD, Kamel-Reidc S.

Leuk Lymphoma. 2004 Mar;45(3):469-80.

PMID:
15160908
15.

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols.

Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G, Testi AM, Avvisati G, Petti MC, Minotti C, Latagliata R, Foà R, Pelicci PG, Lo-Coco F.

Blood. 2012 Jan 5;119(1):49-54. doi: 10.1182/blood-2011-07-369595. Epub 2011 Nov 2.

16.

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8.

17.

[Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].

Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.

Srp Arh Celok Lek. 1995 Nov-Dec;123(11-12):279-85. Serbian.

PMID:
16296239
18.

Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia.

Ottone T, Cicconi L, Hasan SK, Lavorgna S, Divona M, Voso MT, Montefusco E, Melillo L, Barragán E, Platzbecker U, Giannì L, Hubmann M, Pagoni M, Amadori S, Lo-Coco F.

Leuk Res. 2012 Apr;36(4):474-8. doi: 10.1016/j.leukres.2011.10.015. Epub 2011 Nov 8.

PMID:
22071137
19.

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L.

Blood. 1999 Aug 15;94(4):1192-200.

20.

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.

Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan HC, Garcés-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA.

Blood. 2013 Mar 14;121(11):1935-43. doi: 10.1182/blood-2012-08-449918. Epub 2013 Jan 14.

Supplemental Content

Support Center